FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 4,770,000 shares, a drop of 6.8% from the August 31st total of 5,120,000 shares. Based on an average daily volume of 2,180,000 shares, the days-to-cover ratio is currently 2.2 days.

FibroGen Stock Performance

FibroGen stock traded down $0.01 during midday trading on Tuesday, reaching $0.39. 327,163 shares of the company’s stock were exchanged, compared to its average volume of 2,360,875. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93. The firm has a market cap of $38.34 million, a price-to-earnings ratio of -0.16 and a beta of 0.69. The stock’s 50-day simple moving average is $0.50 and its 200 day simple moving average is $1.03.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $50.64 million for the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the prior year, the firm earned ($0.65) EPS. Research analysts forecast that FibroGen will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

A number of institutional investors have recently made changes to their positions in FGEN. Armistice Capital LLC boosted its holdings in shares of FibroGen by 23.7% during the fourth quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after acquiring an additional 1,872,000 shares during the period. Acadian Asset Management LLC boosted its stake in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares during the period. AQR Capital Management LLC boosted its stake in shares of FibroGen by 139.6% in the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares during the period. Pennant Investors LP bought a new stake in shares of FibroGen in the fourth quarter valued at approximately $681,000. Finally, XTX Topco Ltd bought a new stake in shares of FibroGen in the second quarter valued at approximately $424,000. Institutional investors own 72.71% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on FGEN. William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd. StockNews.com assumed coverage on FibroGen in a research report on Friday. They issued a “hold” rating on the stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.